ライフサイエンスコーパス: half life

1 es (quantitative switching and long Z isomer half-life).

2 including its pleiotropic effects and short half-life.

3 otency, greater breadth, and increased serum half-life.

4 s perhaps related to this medication's short half-life.

5 bution, is the preferred means of modulating half-life.

6 at the NEDDylation-deficient HBx has shorter half-life.

7 tokine's active site and prolongation of its half-life.

8 ates antibody cytotoxic activities and serum half-life.

9 , and a few kinases to regulate activity and half-life.

10 ually high ( approximately 5 years) reaction half-life.

11 stinguishable despite the latter's increased half-life.

12 f WDHD1 protein was increased along with the half-life.

13 1 fusokine stabilizes IL-21 and prolongs its half-life.

14 ited because of its peptide nature and short half-life.

15 h bioavailable concentrations and biological half-life.

16 er improvements in MAb potency, breadth, and half-life.

17 interacts with HNF4A protein to regulate its half-life.

18 bioavailability in women and its long tissue half-life.

19 c gene transcription and increase VEGFC mRNA half-life.

20 phagocytosis of merozoites declined rapidly (half-life, 0.15 years).

21 erization rate (6.0 x 10(8) M(-1) s(-1)) and half-life (10 ns) of CO2(*-) can be evaluated by fitting

22 ng/mL), Cmax (19.2 +/- 9.7 ng/mL), apparent Half-life (11.7 +/- 4.2 hours), estimated total body cle

23 h the positron-emitting radionuclide (64)Cu (half-life, 12.7 h).

24 Importantly, thekoffof QAW039 (half-life = 14.4 minutes) was >7-fold slower than the sl

25 tein in the blood and has a long circulation half-life (19 days).

26 multiple ligand binding sites with a plasma half-life ~19days, facilitated by interaction with the h

27 e at a relatively high rate of 0.27 day(-1) (half-life, 2.6 days).

28 lives 1.15 yrs and 33 days) than (Ph)2CH-Br (half-life 23 s).

29 lent phenotypes were much better maintained (half-life, 4-10 years).

30 r in BP than in SP in the first decay phase (half-life, 4.5 vs 8.6 days; P = .001) with no statistica

31 activity retained at 40 degrees C), storage (half life-40days) and operational stabilities (<90 % act

32 s CM-101 demonstrated rapid blood clearance (half-life = 6.8 minutes +/- 2.4) and predominately renal

33 showed Cmax 3.07 muM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hours, CL/F (apparent clearance) 28.9 L/h

34 haracteristics (97% beta(+) decay, 109.8 min half-life, 635 keV positron energy) and high specific ac

35 proteasome inhibition, exhibited a decreased half-life after treatment with panobinostat, and therefo

36 apeutics is their extraordinarily long serum half-life, allowing infrequent dosing with long-lasting

37 exhibited a 5.7-fold increase in circulation half-life, an 8.6-fold increase in bioavailability, and

38 gnificant associations were observed between half-life and 25(OH)D3 (+ve) in pregnancy, and in all gr

39 demonstrated a promising gain in circulatory half-life and absorption time compared to its monovalent

40 m plasma concentration (C max ), elimination half-life and area under concentration-time curve (AUC)

41 The half-life and confounding gamma emissions of (52g)Mn are

42 eneration hypomethylating drug, has a longer half-life and exposure than its active metabolite decita

43 ing peptides, E6, has significantly improved half-life and glucose tolerance in an oral glucose toler

44 cRn) is responsible for maintaining the long half-life and high levels of the two most abundant circu

45 nuclear waste materials because of its long half-life and high radiotoxicity.

46 le RXFP1 agonist with simple structure, long half-life and high stability.

47 (PDT) efficacy is limited by the very short half-life and limited diffusion radius of singlet oxygen

48 However, a key problem is their short half-life and low bioavailability under in vivo conditio

49 neutrophils are end-stage cells with a short half-life and minimal ongoing protein synthesis.

50 ibody also had significantly improved plasma half-life and serum stability in rodents compared with t

51 acterized by high in vivo instability, short half-life and the requirement of several administrations

52 IV sedation, volatile sedation has a shorter half-life and thus may allow more rapid extubation and n

53 siRNA while providing enhanced blood plasma half-life and tumor targeting.

54 he C-terminal S334 markedly increased TIS11b half-life and, unexpectedly, enhanced TIS11b activity on

55 -UBI showed moderate blood clearance (29-min half-life) and predominant renal clearance in nonhuman p

56 euticals may affect their bioactivity, serum half-life, and (bio)chemical stability.

57 N: The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports it

58 abrogated JAK2 ubiquitination, extended JAK2 half-life, and enhanced JAK2 signaling and cell growth i

59 itro iMeg yield and increased in vivo yield, half-life, and functionality of released platelets.

60 e 25(OH)D, a stable isotope for the 25(OH)D3 half-life, and high-resolution quantitative tomography,

61 e high cost of the antibodies, their limited half-life, and immunogenicity.

62 including improved image resolution, longer half-life, and increased production yields.

63 are limited by their non-specificity, short half-life, and insensitive response to therapy.

64 re important for protein expression, protein half-life, and optimal phosphorylation of SAMHD1 at Thr(

65 K(+) with Rb(+) because (42)K(+) has a short half-life, and previous studies showed that K(+)- and Rb

66 AQP2 ubiquitylation, decreased AQP2 protein half-life, and reduced AQP2 levels.

67 ournal-level variables (impact factor, cited half-life, and Standards for Reporting of Diagnostic Acc

68 onditions was extremely efficient and rapid (half-life approximately 25 s).

69 diffusion and the antibiotic-target complex half-life are sufficient to explain which treatment stra

70 est all-round variant with a 3-fold improved half-life at 60 degrees C, 5-fold increased specific act

71 titution at 46, showed a 22-fold increase of half-life at 60 degrees C.

72 was more stable with a prolonged inhibitory half-life at relevant aquaculture temperatures (15 degre

73 tween 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.

74 ne, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with u

75 cellular assays, advantageous exposures and half-life both in animal models and in humans, and in vi

76 levels negatively correlate with transcript half-life but are not required for most pre-mRNA splicin

77 ulted in significant prolongation of Abeta40 half-life, but only in the latter phase of Abeta clearan

78 ynomolgus monkeys, we again observed a short half-life, but were able to demonstrate effective Fcgamm

79 IgG binding to FcRn and thereby shortens IgG half-life by preventing IgGs from recycling back into ci

80 Results of the half-life calculation (t1/2) showed that the storage sta

81 w Pol II mutant strains and the magnitude of half-life changes correlate both with mutants' growth an

82 longer lag phase prior to decay and a longer half-life compared with E. coli DSM1103 (6.64 +/- 0.63 h

83 grees C increase in Tm and a 44-fold greater half-life compared with the wild-type enzyme.

84 DBP, the DBP genotype, and the 25(OH)D3 half-life did not differ between BMI groups.

85 ty was hampered in large part by their short half-life due to excessive hepatic clearance.

86 tibody, has a considerably longer biological half-life (e.g., approximately 107 h in rats).

87 es include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal

88 The geometric mean apparent terminal phase half-life estimated after the third injection was 40 day

89 pted Rho was essentially irreversible with a half-life estimated to be 420 years, until after thermal

90 Neither increased dosing nor half-life extension by fusion of A4 to IgG2a Fc (A4Fc) o

91 divalent small-molecule albumin binders for half-life extension of peptides.

92 omotes FBXW2 ubiquitylation and shortens its half-life, FBXW2 does the same to SKP2.

93 X-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatm

94 Due to long half-life for clearance and degradation, PFOS is accumul

95 (log KOW > 2 and log KOA > 6) as long as the half-life for metabolic elimination is long relative to

96 with 532 nm irradiation, and has a very long half-life for thermal isomerization (t1/2 = 74 d at 25 d

97 polyubiquitination level and shortening its half-life from 24 h to approximately 3.5 h.

98 Drug half-life has important implications for dosing regimen

99 serum albumin to tune the blood circulatory half-life, hepatic accumulation and gene silencing; base

100 The benefit of long half-life, however, carries with it liabilities.

101 on a scale of one to six based on the median half-life in a data set compiled from literature-reporte

102 f CR3 reduces soluble Abeta levels and Abeta half-life in brain interstitial fluid (ISF), as measured

103 nal PBM mutation but no change in total NHE3 half-life in either.

104 le clinical candidate, due to its very short half-life in humans.

105 ile of a high peak to trough ratio and short half-life in humans.

106 ria-specific antibodies and a prolonged IgG3 half-life in infants and that its presence correlates wi

107 s even after gel filtration, has a prolonged half-life in mice transgenic for human alphaIIb compared

108 ndirectly regulating platelet reactivity and half-life in mice.

109 r 16.9% of the observed variability of FVIII half-life in our cohort.

110 isolates also similar to that of 10E8, and a half-life in rhesus macaques of approximately 10 days.

111 A short half-life in the circulation limits the application of t

112 antibodies (VHHs) is limited by their short half-life in the circulation.

113 ause of their intrinsic instability and long half-life in the outer segment, but also highlights the

114 However, it has a short half-life in the presence of human liver microsomes (HLM

115 However, metabolic testing revealed a short half-life in the presence of mouse hepatocyte fractions.

116 IFN induced gene expression, and a decreased half-life in transfected cells compared to eVP24 or rVP2

117 Because 3-MeA has a short half-life in vitro, we used the stable 3-deaza analog, 3

118 developed as a technique to extend the serum half-life in vivo by taking advantages of unusually long

119 s leading to rapid degradation and shortened half-life in vivo Here we present a proof of concept stu

120 ulate FcRn interaction in vitro and antibody half-life in vivo This is an important first step in dev

121 etectable for 56-177 days, depending on bNAb half-life in vivo.

122 gulate Cdc25C protein levels by reducing its half-life independently of the presence of p53.

123 Half-life is a key parameter for optimization in researc

124 Extension of the serum half-life is an important issue in developing new therap

125 and fibrotic diseases, but its short in vivo half-life is an obstacle to long-term administration.

126 art because a hydrophobic statin with a long half-life is necessary.

127 haracteristic of antibodies that drives long half-life is the ability to interact with the recycling

128 If the half-life is too long, the time over which accumulation

129 If the half-life is too short, it may require more frequent dos

130 iduals, the absolute reduction in VWF plasma half-life is usually mild and not sufficient to signific

131 for half the extinction debt to be paid off (half-life), is crucial for conservation purposes.

132 d epithelia are rapidly replenished by short half-life langerin-expressing monocyte-derived LCs (MDLC

133 ctors), transcript abundance (AGO2) and mRNA half-life (m6A).

134 Because of their remarkably long half-life, matrix proteins, like type I collagen and ela

135 t apoE3, significantly increased brain Abeta half-life measured by in vivo microdialysis.

136 The particle's short blood half-life, measured in three species, including a primat

137 eral of which were validated individually by half-life measurements and quantification of their 5'-te

138 ta from ribosome profiling, RNA-Seq and mRNA half-life measurements that support distinct roles for S

139 significantly associated with shorter FVIII half-life (median, 7.8 hours [interquartile range, 6.6-9

140 lite of tianeptine (MC5), which has a longer half-life, mimics the behavioral effects of tianeptine i

141 vascular indications is limited by its short half-life, necessitating a three times daily dosing regi

142 ing pericardial administration, displaying a half-life of 2.5days in the heart.

143 long-term presence within the heart, with a half-life of 7days.

144 ileptic foci and brain tumors, but the short half-life of (11)C limits its widespread clinical applic

145 -PSMA-617 scans extrapolated to the physical half-life of (225)Ac, assuming instant decay of unstable

146 ance was biexponential, with a mean biologic half-life of 0.3 h (58%) for the rapid alpha phase and 6

147 y water analysis gave a better-defined blood half-life of 0.77 +/- 0.14 days (18.5 hours), close to g

148 ki's rule for a drug-like molecule and has a half-life of 1 h in a pharmacokinetics study and a reaso

149 se reducing moieties are short-lived (with a half-life of 1.9 h) and easily oxidized in air-saturated

150 ce was monoexponential, with a mean biologic half-life of 1.95 h, whereas blood clearance was biexpon

151 e, with lysosomal-delivered MPO exhibiting a half-life of 10 h.

152 duct of the now-extinct (146)Sm (which has a half-life of 103 million years), this (142)Nd difference

153 e 16-TP in live cells demonstrated favorable half-life of 11.6 h, suggesting once-a-day dosing.

154 e-proportional pharmacokinetic profile and a half-life of 12 days.

155 voralstat was bi-exponential with a terminal half-life of 12-31 h.

156 A half-life of 12-48 h is generally ideal for once daily d

157 iolabeled with (64)Cu, a radionuclide with a half-life of 12.7 h, ideal for PET imaging.

158 We then showed that the long pharmacokinetic half-life of 15a combined with the high drug concentrati

159 Orthophenylphenol dissipated with a half-life of 15days.

160 acokinetic properties, including a predicted half-life of 16-19 h.

161 plasma followed a single exponential with a half-life of 17.0 +/- 4.2 min.

162 y processed in human liver microsomes with a half-life of 2 min.

163 from the liquid medium after 21 days with a half-life of 2.1 days.

164 An estimated average intrinsic elimination half-life of 2.4 years (1.8-3.1 years accounting for var

165 was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexp

166 this model, the linker with a plasma release half-life of 21h achieved sustained SN-38 exposure in bl

167 10-1074 was well tolerated and had a half-life of 24.0 d in participants without HIV-1 infect

168 not be explained by lower DBP or the shorter half-life of 25(OH)D3 We speculate that low 25(OH)D in o

169 re 4 degrees C (89.6%), with an extrapolated half-life of 277days.

170 A half-life of 280 min was measured for the polymeric dono

171 exponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L).

172 centration around 24 hours, with an apparent half-life of 4 to 5 days and approximately 50% accumulat

173 nst solid tumors is limited due to its short half-life of 45min in humans.

174 to maximum concentration, 1-2 hours), with a half-life of 5.2 to 10.9 hours.

175 Overall, rFIXFc exhibited a prolonged half-life of 68.6 h (95% CI 61.8-76.0), reduced clearanc

176 detectable oil hydrocarbons has an apparent half-life of 7-14 days.

177 g on rate of return to clinic decayed with a half-life of 7.0 days after tracing (95% CI, 2.6 %-12.9%

178 cally relevant conditions revealed a release half-life of 75 min for the small molecule NTA under inv

179 2.52), corresponding to a parasite clearance half-life of 9.4 h (8.7-10.2) and 6.2 h (5.7-6.7), respe

180 between doses of 3 mg/kg and 20 mg/kg and a half-life of 95-99 h (3.9-4.1 days) at the 10 mg/kg and

181 The functional half-life of a particular mRNA, which affects how much p

182 the general observation that the biological half-life of a protein drug is significantly longer in h

183 d in the skin, tongue, and esophagus, with a half-life of about 1 month.

184 -shift to the corresponding aldehyde with an half-life of about 10 s, evidenced by isomer-selective t

185 The average half-life of anthocyanin color increased from 2 days to

186 ls dies through abortive infection and has a half-life of approximately 2.6 days.

187 -NIR afterglow luminescence at 780 nm with a half-life of approximately 6 min.

188 hagocytic cells markedly prolonged the serum half-life of asparaginase in vivo and decreased drug upt

189 ced 1,2-D-shift reactivity with an estimated half-life of at least 200 s under the experimental condi

190 of beta-carotene degradation showed that the half-life of beta-carotene is extended from less than 4

191 lobulinemia in which we documented the short half-life of both total and allergen-specific IgE in ser

192 tting approach, we found that shortening the half-life of Cas9 in fertilized zygotes reduces mosaic m

193 t, and NOX4 has significantly increased mRNA half-life of CCR2 and CCL2 in conjunction with Ser221 ph

194 effector differentiation correlated with the half-life of CD1d-lipid-TCR interactions.

195 ls overexpressing cellular HuR increased the half-life of COX-2 mRNA, promoted COX-2 protein expressi

196 COX-2 at the mRNA level, but it reduced the half-life of COX-2 protein, which was restored by COX-2

197 In absence of ADAR2, the abundance and half-life of Ctn RNA are significantly reduced.

198 a reduces the protein level and shortens the half-life of cytoplasmic Plk3 in a ubiquitin-proteasome-

199 tment should be interrupted according to the half-life of each drug.

200 er, PTPRO phosphatase activity shortened the half-life of ERBB2 by increasing endocytotic degradation

201 recently reported that the long circulatory half-life of FX is linked to its interaction with liver-

202 ption of the LOG2 gene increased the in vivo half-life of GDU1, mass spectrometry confirmed that LOG2

203 eling of mammals revealed that, in vivo, the half-life of GFAP in mutant mice (15.4 +/- 0.5 days) was

204 lencing FBXO17 gene expression increased the half-life of GSK3beta in cells.

205 vo, in a mouse ITP model we observed a short half-life of hexameric-Fc but were nevertheless able to

206 The estimated mean half-life of HIV-1 DNA from VS was 15.9 years and was sh

207 by taking advantages of unusually long serum half-life of human serum albumin (HSA).

208 ditional receptors contribute to the reduced half-life of hyposialylated VWF.

209 nesis induced by a single CCl4 injection the half-life of I125-labeled pPB-HSA at 40 min and confirme

210 cussion of the existing literature about the half-life of IgE in both the circulation and skin.

211 reduced transplacental transfer and reduced half-life of IgG3 in vivo.

212 the parental antibodies prolonged the serum half-life of IL-6.

213 humans is consistent with a blood neutrophil half-life of less than 1 day.

214 rom the cell surface to lysosomes and have a half-life of less than two hours.

215 Rn increases the transplacental transfer and half-life of malaria-specific IgG3 in young infants and

216 inistration of FXN LNPs, suggesting that the half-life of mFXN in vivo exceeds one week.

217 KTs, we show that KT-derived MTs shorten the half-life of noncaptured KTs from 48-49 s to 28-34 s.

218 mical handle that alone would enjoy the long half-life of normal antibodies but, upon addition of a s

219 Despite a short half-life of OS47720 in mouse brain, a single intraperit

220 Studies on the intracellular half-life of phosphoramidate 16-TP in live cells demonst

221 hed SUMOylation, significantly increased the half-life of PIM1, and markedly reduced its ubiquitylati

222 The long half-life of piperaquine makes it attractive for IPT.

223 e report a method to extend the intravitreal half-life of protein drugs as an alternative to either e

224 The tissue half-life of proteins largely determines treatment frequ

225 Sialylation regulates the in vivo half-life of recombinant therapeutic glycoproteins, affe

226 r that has confounded attempts to extend the half-life of rFVIII.

227 thioester reformation, which occurred with a half-life of several minutes.

228 assess the biophysical properties and serum half-life of the aglycosylated IgG variants to measure s

229 Moreover, the serum half-life of the amphiphile bound to the cage and the pr

230 by dNTPs are in the 2-20 mum range, and the half-life of the assembled tetramer after deoxynucleotid

231 the persistence of intoxication is the long half-life of the catalytic light chain, which remains en

232 However, MB and HIFU are limited by the half-life of the contrast agent and challenges in accura

233 poses generally starts by matching the serum half-life of the mAb or antibody-related therapeutic and

234 tion as measured by a slight increase in the half-life of the model protein when its degradation was

235 administered to rabbit and monkey eyes, the half-life of the modified proteins is increased approxim

236 Cells that lack Coy1 displayed a reduced half-life of the Och1 mannosyltransferase, an establishe

237 bly feature enhances biodistribution and the half-life of the peptides, while integration into the ta

238 4) There was a significant reduction in half-life of the PM pool of NHE3 in only the internal PB

239 uclease activity of RNase J1, increasing the half-life of the primary transcript and concomitantly en

240 ns are required due to the short circulating half-life of the protein.

241 ntibody-related therapeutic and the physical half-life of the radionuclide.

242 We managed to increase the half-life of the second VHF-to-DHA conversion from 65 to

243 rs, they can also significantly increase the half-life of their ligands by FcRn-mediated antibody rec

244 However, the short half-life of these therapeutic proteins requires multipl

245 taE=17.7 to 47.5); and reduced the predicted half-life of total anthocyanins (ranging from 1.8 to 3we

246 Kuhl et al. attempted to determine the half-life of type VII collagen in the skin, tongue, and

247 ting Thr(60) or Ser(64) to Ala increases the half-life of UNG2, reduces the rate of in vitro uracil e

248 e red blood cells to prolong the circulatory half-life of VHHs.

249 Therefore, the half-life of VWF ( approximately 15 hours) appears to be

250 the nanocapsule exhibited a long circulation half-life of ~45h, a three-fold increase from the unmodi

251 ability of Rho showed that Rho decays with a half-life on the order of days.

252 An effective approach to half-life optimization requires an understanding of the

253 e theory and are able to derive the physical half-life or residence time for TATA-binding protein (TB

254 , a commonly used cephalosporin with a short half-life, over 2-5 min (combined with 500 mg metronidaz

255 ommon, especially for patients given shorter half-life pharmacotherapies and who boarded in the emerg

256 Others are radiolabeled with the short-half-life positron emitter carbon-11, which is rather im

257 ves followed the first-order kinetic and its half-life ranged from 3.43 to 3.81 days.

258 controlled drug release, improved biological half-life, reduced toxicity and targeted delivery.

259 ange of biological phenomena such as protein half-life regulation, protein-protein and protein-membra

260 We therefore exploited a short-half-life Rex1::GFP reporter to isolate cells either sid

261 adionuclides with a relatively long physical half-life, such as (89)Zr.

262 vid) is an amyloid-binding PET ligand with a half-life suitable for clinical use outside of the resea

263 generator-produced radionuclide with a short half-life (t(1/2) = 68 min) that is particularly well su

264 OTA exhibited a significantly shorter plasma half-life (T(1/2)=14.4h) when compared to the remote-loa

265 The median biologic half-life T1/2beta was 111 h (range, 78-193 h).

266 ATM results indicate that half-life (t1/2) and percent decreases for PCDD/Fs, CP-P

267 aggedbeta2 adrenoceptor at a slow rate, with half-life (t1/2) values of 0.78 +/- 0.1 and 0.78 +/- 0.0

268 The half-life (t1/2) values of the particles ranged from 7 (

269 90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration

270 tes at ambient conditions in water and has a half-life, tau1/2 = 2 h.

271 gassed acetone at 295 K, the radical 2 has a half-life, tau1/2 = 49 h (DeltaH(double dagger) = 17.9 +

272 ant of the human PGC1A protein had a shorter half-life than the glycine 482 variant when expressed in

273 ministration of a cephalosporin with a short half-life, thereby obviating the need for increasingly c

274 beta-TrCP1 levels by shortening its protein half-life through promoting its ubiquitylation via atypi

275 nning NMR reveals that solid heptacene has a half-life time of several weeks at room temperature.

276 he central point of the experimental domain, half-life times of curcumin, demethoxycurcumin and bisde

277 nactivates decitabine, severely limiting its half-life, tissue distribution, and oral bioavailability

278 Ranging from extended half-life to nonfactor products and gene therapy, these

279 ntaining SRSF6 transcript exhibits a shorter half-life upon rapamycin-treatment as compared to the no

280 stranded on a shoreline; there the apparent half-life varies from many months to many years.

281 An empirical relaxation half-life vs. area relationship for tropical bird commun

282 The antibody-drug conjugate's mean half-life was 16.5 hours for the four cohorts.

283 The linezolid extracellular half-life was 2.64 +/- 0.38 hours, whereas intracellular

284 The median biologic whole-body retention half-life was 370 h (range, 257-578 h).

285 tream compared to free SOD1 or SC nanozymes (half-life was 60 vs 6min).

286 /L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minu

287 s 2.64 +/- 0.38 hours, whereas intracellular half-life was 8.93 +/- 1.30 hours (r(2) = 0.89).

288 The (13)C-EPA plasma half-life was approximately 2 d for both young and old m

289 adelumab were observed; the mean elimination half-life was approximately 2 weeks.

290 The (13)C-AA plasma half-life was approximately 4.4 d in both young and old

291 25(OH)D3 half-life was not significantly different between groups

292 ith the IgG3-H435 variant, a 28% longer IgG3 half-life was noted (95% CI 4%, 59%, p = 0.02) compared

293 in D binding protein (DBP), PTH and 25(OH)D3 half-life were measured in third-trimester pregnant wome

294 evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene e

295 or with potent antiviral activity and a long half-life when administered by injection that prevented

296 J plaque size and increased connexin protein half-life, while maintaining GJ channels in an open, fun

297 ring resulted in analogues with a prolonged half-life, while the biphenyl moiety revealed the most p

298 anscription factors, KLF4 has a rather short half-life within the cell and its turnover must be caref

299 onment; some of them were characterized by a half-life within the timescale of physiological DNA proc

300 7ii showed high liver distribution and long half-life without obvious hepatotoxicity.